Terazosin

When ATH:
C02CA05

Characteristic.

The white crystalline powder, without smell, soluble in water.

Pharmacological action.
Vasodilating, antidizuricescoe, gipolipidemicescoe.

Application.

Arterial hypertension, benign prostatic hyperplasia.

Contraindications.

Hypersensitivity, hypotension, pregnancy, lactation, childhood.

Restrictions apply.

IBS and other heart disease, kidney and / or liver failure, cerebrovascular accident, Hypertensive retinopathy of the III or IV degree, diabetes mellitus type 1.

Side effects.

Weakness, fatiguability, drowsiness, anxiety, headache, dizziness, paraesthesia, decreased libido, blurred vision, noise in ears, "Phenomenon of the first dose" (a sharp drop in blood pressure, up to orthostatic collapse, After the first trick, more often in combination therapy with diuretics or beta-blockers), gipotenziya, tachycardia, Arrhythmia, peripheral edema, cough, bronchitis, xerostomia, pharyngitis, nausea, vomiting, arthralgia, myalgia, decrease in hematocrit and hemoglobin levels, leukopenia, hypoalbuminemia, hypoproteinemia, flu-like symptoms, allergic reactions.

Cooperation.

Enhances the hypotensive activity of diuretics, adrenoblokatorov, calcium antagonists, myotropic drugs and drugs, inhibiting the renin-angiotensin-aldosterone system.

Antacids and adsorbents reduce absorption. Adrenergic agonists reduce effectiveness.

Overdose.

Symptoms: tachycardia, gipotenziya, Orthostatic hypotension.

Treatment: Transfer the patient to a horizontal position, with the head of the bed down, in / in a liquid, hypertensive drugs. Hemodialysis nyeeffyektivyen. No specific antidote.

Dosing and Administration.

Inside. By 1 mg once before bed; the dose is gradually increased to 10–20 mg (no more) 1 once a day.

Precautions.

After the first reception or in the initial period of treatment, the “first dose” may occur. To prevent orthostatic collapse, the initial dose should not exceed 1 mg and should be administered before bedtime (in the supine position). Reducing body fluid volume and limiting salt intake increases the risk of postural hypotension. It must be remembered, that similar phenomena can occur when treatment is resumed after a break of several days. In such cases, treatment should be resumed with a dose 1 mg.

Fainting occurs in 1% cases. The development of fainting can be caused by a rapid increase in dosage after the “first dose effect” occurs., as well as the prescription of doxazosin in combination with diuretics and/or other antihypertensive drugs.

Before starting treatment for BPH, it is necessary to exclude the presence of a malignant neoplasm.. In patients with BPH, blood pressure levels should be monitored at the beginning of treatment and when changing the dose of the drug during treatment.. It is advisable to evaluate the effectiveness of doxazosin for BPH after 4–6 weeks of treatment with maintenance doses..

At the beginning of treatment and when increasing the dose of the drug, patients are not recommended to engage in potentially hazardous activities, require increased attention and psychomotor speed reactions (incl. driving vehicles). Further, during treatment, These restrictions are set individually.

Cooperation

Active substance	Description of interaction
Amlodipine	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Atenolol	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Betaksolol	FMR: synergism. Strengthens (mutually) hypotensive effect; combined use may require dose reduction.
Bisoprolol	FMR: synergism. Strengthens (mutually) hypotensive effect; combined use may require dose reduction.
Valsartan	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant decrease in blood pressure is possible, requiring dose reduction.
Verapamil	FKV. FMR. Strengthens (mutually) hypotensive effect, increases (1.2–1.3 times) AUC0–24, Cmax and Cmin.
Gidroxlorotiazid	FMR: synergism. Strengthens (mutually) gipotenziю; when administered in combination, the dose must be reduced.
Diltiazem	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Doksazozin	FMR: synergism. Strengthens (mutually) hypotensive effect; combined use may require dose reduction.
Dopamine	FMR. Terazosin reduces the peripheral pressor effect.
Indapamid	FMR: synergism. Strengthens (mutually) gipotenziю; when administered in combination, the dose must be reduced.
Indomethacin	FMR. Weakens the antihypertensive effect (inhibits the synthesis of prostaglandins in the kidneys, causes sodium and fluid retention).
Irbesartan	FMR: synergism. Strengthens (mutually) hypotensive effect; combined use may require dose reduction.
Candesartan cïleksetïl	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Captopril	FMR: synergism. Strengthens (mutually) effects, incl. side; combined use requires caution.
Klonidin	FMR: synergism. Strengthens (mutually) hypotensive effect; when administered in combination, excessive hypotension is possible, requiring dose adjustment.
Lisinopril	FMR: synergism. Strengthens (mutually) hypotensive effect; concomitant use may require dose reduction.
Lozartan	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Methyldopa	FMR: synergism. Strengthens (mutually) hypotensive effect; joint application requires dose reduction.
Metoprolol	FMR: synergism. Strengthens (mutually) hypotensive effect; When used together, reduction of doses may be required.
Minoksidil	FMR: synergism. Strengthens (mutually) hypotensive effect; Combined use can cause a significant drop in blood pressure, requiring dose reduction.
Moexipril	FMR: synergism. Strengthens (mutually) hypotensive effect; the combined appointment may require dose reduction.
Nadolol	FMR: synergism. Strengthens (mutually) hypotensive effect; When used together, reduction of doses may be required.
Nitroglycerin	FMR: synergism. Enhances the risk of developing significant hypotension; the combined appointment may require dose reduction.
Nifedipine	FMR: synergism. Strengthens (mutually) hypotensive effect; combined use may cause a significant drop in blood pressure, requiring dose reduction.
Perindopril	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a sharp decrease in blood pressure is possible, requiring dose reduction.
Pindolol	FMR: synergism. Strengthens (mutually) hypotensive effect; When used together, reduction of doses may be required.
Prazosin	FMR: synergism. Strengthens (mutually) hypotensive effect; Significant hypotension may occur when administered together, requiring dose adjustment.
Propranolol	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Ramipril	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a sharp decrease in blood pressure is possible, requiring dose reduction.
Risperidone	FMR: synergism. Enhances the hypotensive effect.
Sotalol	FMR: synergism. Strengthens (mutually) hypotensive effect; Joint application may require reduction of doses.
Spirapril	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a sharp decrease in blood pressure is possible, requiring dose reduction.
Telmisartan	FMR: synergism. Strengthens (mutually) hypotensive effect; Joint application may require reduced doses.
Timolol	FMR: synergism. Strengthens (mutually) hypotensive effect; Joint application may require reduction of doses.
Trandolapril	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a sharp decrease in blood pressure is possible, requiring dose reduction.
Felodipine	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a significant drop in blood pressure is possible, requiring dose reduction.
Phenylephrine	FMR. Terazosin may reduce the pressor effect and shorten the duration of action.
Fosinopril	FMR: synergism. Strengthens (mutually) hypotensive effect, possible sharp drop in blood pressure; the combined appointment is necessary to reduce the dose.
Furosemid	FMR: synergism. Strengthens (mutually) hypotensive effect; concomitant use may require dose reduction.
Xlortalidon	FMR: synergism. Strengthens (mutually) hypotensive effect; concomitant use may require dose reduction.
Enalapril	FMR: synergism. Strengthens (mutually) hypotensive effect, possible sharp drop in blood pressure; the combined appointment is necessary to reduce the dose.
Enalaprilat	FMR: synergism. Strengthens (mutually) hypotensive effect; with combined use, a sharp drop in blood pressure is possible, requiring dose reduction.
Epinephrine	FMR: antagonizm. With terazosin, the pressor effect is weakened and severe hypotension and tachycardia may develop. (stimulation of beta-adrenergic receptors with blocked alpha-adrenergic receptors).
Esmolol	FMR: synergism. Strengthens (mutually) hypotensive effect; Joint application may require reduction of doses.
Ephedrine	FMR: antagonizm. With terazosin, the pressor effect is weakened and severe hypotension and tachycardia may develop. (stimulation of beta-adrenergic receptors with blocked alpha-adrenergic receptors).